CH517097A - 1 nitro 9 dialkylaminoalkylamino acridine oxides with - Google Patents
1 nitro 9 dialkylaminoalkylamino acridine oxides withInfo
- Publication number
- CH517097A CH517097A CH1526771A CH1526771A CH517097A CH 517097 A CH517097 A CH 517097A CH 1526771 A CH1526771 A CH 1526771A CH 1526771 A CH1526771 A CH 1526771A CH 517097 A CH517097 A CH 517097A
- Authority
- CH
- Switzerland
- Prior art keywords
- nitro
- acridine
- oxides
- dialkylaminoalkylamino
- oxide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
1-nitro-9-dialkylaminoalkylamino-acridine oxides with antitumour activity. G3A. are new cmpds. of formula (I) (where R1 = linear of branched alkylene, particularly propylene; and R2 = lower alkyl, esp. methyl), the corresponding omega-N-oxide, the N10, N10-dioxide and salts and are prepared by oxidation of the parent bases with perbenzoic acid in CHCl3 at 5 to 30 degrees C; or the 1-nitro-9-chloro-, -9-phenoxy- or 9-alkoxyacridine-N-oxides, or the 1-nitro-9-chloroacridine-N-oxide/pyridine complex, is heated with a dialkylaminoalkylamine in phenol at 80-120 degrees for 30-120 mins. - The products and their salts have low toxicity and exhibit pronounced antitumour activity.
Description
Verfahren zur Herstellung neuer, biologisch aktiver 1-Nitro-9-(dialkylaminoalkyl)-akidin-N10,Nw-dioxide Die Erfindung betrifft ein Verfahren zur Herstellung neuer, biologisch aktiver 1-Nitro-9-(dialkylaminoalkyl- amino)-akridin-N10,Nw-dioxide der Formel
EMI0001.0002
worin R, ein gerad- oder verzweigtkettiger Alkylenrest ist und R., Niederalkyl bedeutet.
Diese Derivate bilden eine Gruppe von Verbindungen, die eine starke biologische und insbesondere Antitumor- Wirkung aufweisen. Wie aus den Literaturangaben her vorgeht, waren diese Verbindungen bisher nicht bekannt und deshalb ist auch die Entdeckung ihrer Antitumor- Eigenschaften vollkommen neu.
Das erfindungsgemäss erhaltene 1-Nitro-9-(3'-dime- thylaminopropylamino)-akridin N10,Nw-dioxid geprüft ge- mäss nachstehend angegebenen Methoden, die zur vor klinischen Beurteilung des Wertes neuer Verbindungen angewandt werden, weist Antitumor-Wirkung auf.
Prüfungen in vitro: Bei der Zucht von Krebsgewebe der Linie KB (Tumor menschlicher Herkunft) bewirkt die obige Verbindung die Inhibition um 507, der Albu minanwachsens (LD50) bei einer Konzentration von 10-7 g/ml, beim Miyamura-Test weist sie eine starke Wir kung auf - die Inhibitionszone der Aktivität der Dehy- drogenasen der Ehrlich-carcinom-Zellen beträgt bei einer Konzentration von 1 mg/ml 20 mm, hemmt den Wuchs der Keime der Kresse um 55% bei einer Konzentration von 1 mg/ml.
Prüfungen in vivo: hemmt den Wuchs des Crocker- Sarkom (Sa 180) bei Mäusen um 60% bei Verabreichung einer Dosis von 8 mg/kg an fünf aufeinanderfolgenden Tagen.
Diese Verbindungen zeichnen sich durch eine niedri gere Toxizität aus bei gleichzeitiger Beibehaltung der Antitumor-Eigenschaften im Vergleich mit 1-Nitro-9-(di- alkylamino - alkylamino) - akridin - Derivaten, die keine Sauerstoffatome an Stickstoffatome in den Positionen Nil, und Nw besitzen.
Das erfindungsgemässe Verfahren ist dadurch gekenn zeichnet, dass man auf das N10-Oxid eines entsprechenden 1-Nitro-9-(dialkylaminoalkylamino)-akridins in Gegen wart eines Lösungsmittels und bei einer Temperatur von weniger als<B>50C</B> ein Oxydationsmittel einwirken lässt.
Als Oxydationsmittel werden vorzugsweise Perbenzoe- oder Perphtbalsäure verwendet und das bevorzugte Lö sungsmittel ist Chloroform.
Erhaltene, neue Verbindungen können in ihre Säure additionssalze überführt werden.
<I>Beispiel</I> Einer Chloroformlösung von 1,7 g 1-Nitro-9-(3'-di- methylaminopropylamino)-akridin-N10-oxid, abgekühlt bis zu einer Temperatur von 5"C, wird eine Chloroform lösung von 0,8 a Perbenzoesäure zugegeben und das Ge misch<B>5</B> Stunden lang bei einer Temperatur von unter halb 51>C abgestellt. Durch Zugabe einer ätherischen Chlorwasserstofflösung wird 1, -Nitro-9-(3'-dimethylamino- propylamino)-akridin - N10,Nw-dioxid-bis-hydrogenchlorid mit einem Schmelzpunkt von 21211C unter Zersetzung und einer Ausbeute von 45% ausgefällt.
Process for the production of new, biologically active 1-nitro-9- (dialkylaminoalkyl) -akidin-N10, Nw-dioxides The invention relates to a process for the production of new, biologically active 1-nitro-9- (dialkylaminoalkyl-amino) -akridine-N10 , Formula nw-dioxide
EMI0001.0002
wherein R, is a straight or branched-chain alkylene radical and R., is lower alkyl.
These derivatives form a group of compounds that have a strong biological and, in particular, anti-tumor activity. As can be seen from the literature, these compounds were not previously known and therefore the discovery of their anti-tumor properties is completely new.
The 1-nitro-9- (3'-dimethylaminopropylamino) -akridine N10, Nw-dioxide obtained according to the invention, tested according to the methods given below, which are used to assess the value of new compounds prior to clinical assessment, has anti-tumor activity.
In vitro tests: In the cultivation of cancerous tissue of the KB line (tumor of human origin), the above compound causes inhibition by 507, of albumin growth (LD50) at a concentration of 10-7 g / ml, in the Miyamura test it has a strong effect - the zone of inhibition of the activity of the dehydrogenases of Ehrlich's carcinoma cells is 20 mm at a concentration of 1 mg / ml, inhibits the growth of the cress germs by 55% at a concentration of 1 mg / ml.
In vivo tests: inhibits the growth of Crocker's sarcoma (Sa 180) in mice by 60% when administered at a dose of 8 mg / kg for five consecutive days.
These compounds are characterized by a lower toxicity while at the same time retaining the anti-tumor properties in comparison with 1-nitro-9- (dialkylamino-alkylamino) -acridine derivatives, which do not contain oxygen atoms to nitrogen atoms in the Nil, and Nw positions have.
The process according to the invention is characterized in that an oxidizing agent is applied to the N10 oxide of a corresponding 1-nitro-9- (dialkylaminoalkylamino) acridine in the presence of a solvent and at a temperature of less than 50C can act.
Perbenzoic or perphthalic acid are preferably used as the oxidizing agent and the preferred solvent is chloroform.
New compounds obtained can be converted into their acid addition salts.
<I> Example </I> A chloroform solution of 1.7 g of 1-nitro-9- (3'-dimethylaminopropylamino) -akridine-N10-oxide, cooled to a temperature of 5 "C, becomes a chloroform solution of 0.8 a perbenzoic acid is added and the mixture is shut off for 5 hours at a temperature below 50 ° C. By adding an ethereal hydrogen chloride solution, 1, -nitro-9- (3'-dimethylamino - Propylamino) -akridine - N10, Nw-dioxid-bis-hydrogen chloride with a melting point of 21211C precipitated with decomposition and a yield of 45%.
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL128855A PL66626B1 (en) | 1968-08-31 | ||
CH1220469A CH517096A (en) | 1968-08-31 | 1969-08-12 | Process for the production of new, biologically active 1-nitro-9- (dialkyl-aminoalkylamino) -akridine-N10-oxides |
Publications (1)
Publication Number | Publication Date |
---|---|
CH517097A true CH517097A (en) | 1971-12-31 |
Family
ID=25709821
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH1526671A CH524606A (en) | 1968-08-31 | 1969-08-12 | Process for the production of new, biologically active 1-nitro-9- (dialkylaminoalkylamino) -akridine-Nw-oxides |
CH1526771A CH517097A (en) | 1968-08-31 | 1969-08-12 | 1 nitro 9 dialkylaminoalkylamino acridine oxides with |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH1526671A CH524606A (en) | 1968-08-31 | 1969-08-12 | Process for the production of new, biologically active 1-nitro-9- (dialkylaminoalkylamino) -akridine-Nw-oxides |
Country Status (1)
Country | Link |
---|---|
CH (2) | CH524606A (en) |
-
1969
- 1969-08-12 CH CH1526671A patent/CH524606A/en not_active IP Right Cessation
- 1969-08-12 CH CH1526771A patent/CH517097A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CH524606A (en) | 1972-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0049852B1 (en) | Pharmaceutical formulation and its preparation | |
DE1595876A1 (en) | Process for the preparation of aminomethyl derivatives of Rifamycin SV | |
DE1802162A1 (en) | New N-pyridylmethylidene homocysteine thiolactone compound and process for its preparation | |
DE1238909B (en) | Process for the preparation of diacylcymarols | |
CH517097A (en) | 1 nitro 9 dialkylaminoalkylamino acridine oxides with | |
DE1942185C3 (en) | N-oxides of l-nitro-9- (dialkylaminoalkylamino) acridines | |
AT349481B (en) | METHOD FOR PRODUCING NEW MORPHOLINE DERIVATIVES, THEIR N-OXIDES AND SALTS | |
US2100054A (en) | Anesthetic tannate | |
DE2835987A1 (en) | 3-AMINO-17A-AZA-D-HOMO-5 ALPHA ANDROSTAN DERIVATIVES AND QUATERNAAL SALTS THEREOF AND METHOD FOR THE PRODUCTION THEREOF | |
DE2549863C3 (en) | Pyridoxylidene-p-aminobenzoic acid derivatives, their preparation and use | |
DE2164988C3 (en) | 2,2-Diphenylcyclopropanecarboxylic acid ester derivatives, processes for their preparation and pharmaceuticals containing them | |
DE561314C (en) | Process for the production of easily soluble salts of high molecular weight iodized fatty acids | |
AT343138B (en) | PROCESS FOR PRODUCING NEW PHOSPHINYL DERIVATIVES | |
US2752344A (en) | Piperazine glycolylarsanilate | |
AT206895B (en) | Process for the preparation of a new salt of piperazine with 2,4,5-trichlorophenol | |
AT338288B (en) | PROCESS FOR MANUFACTURING NEW 7.7'-BRIDGED BIS-THEOPHYLLINE | |
DE1944758C3 (en) | 1 -Cinnamoyl ^ -methyl-S-methoxy-Sindolylessigsäureester, process for their preparation and medicinal products | |
DE2235745C3 (en) | 2-amino-2 ', 6'-propionoxylidide. Process for its production and pharmaceuticals containing it | |
DE1493253C (en) | ||
AT203508B (en) | Process for the preparation of new substituted 3,5-dioxo-tetrahydro-1,2,6-thiadiazine-1,1-dioxyden | |
DE1919895C (en) | 2 phenyl 2 morpholinomethyl indan 1.3 dione | |
DE961346C (en) | Process for the preparation of phosphorus-containing derivatives of aromatic or heterocyclic carboxylic acid hydrazides | |
DE2028330C3 (en) | Thiophosphorimide-isoquinoline adducts and agents containing them | |
CH410985A (en) | Process for the preparation of addition compounds of sulfonic acid hydrazides with organic sulfonic acids | |
DE1695998B2 (en) | N HIGH 2, N HIGH 3-DI-SPIRO-TRIPIPERAZINIUM SALT AND METHOD FOR MAKING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |